MAOA and Alzheimer disease: Actually,AD treatment mainly involves the administration of orally active AChEinhibitors exerting merely palliative, symptomatic relief.14 Monoamine oxidases A and B (MAO A and B) areenzymes cleaving the Cα–N bond of severalarylalkylamines (including xenobiotics and neurotransmitters suchas dopamine) upon a FAD-dependent oxidative deamination reaction.15 MAO A and B are validated drug targets for depressionand for PD, respectively, whereas, more recently, a renewed interestin these enzymes arose from their role in cardiac senescence16 and other age-related disorders, as for AD.17−19